Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia and bacterial infections, Daiichi Sankyo is also engaged in the development of treatments for thrombotic disorders and focuses on the discovery of novel oncology and cardiovascular-metabolic therapies. more...
Like other research-based pharmaceutical companies, Daiichi Sankyo is engaged in high-risk/high-return research and development investments. But the growth rates of the pharmaceutical markets in industrialised countries are low. more...
In fiscal year 2010, Daiichi Sankyo increased its net sales from €7.56 billion to €8.55 billion. Net income rose to €619.8 million. These results were achieved by about 30,500 employees worldwide. more...
In Europe, Daiichi Sankyo is also dedicated to the creation and supply of innovative pharmaceutical products to address the diversified unmet medical needs of patients. In Europe, the company's roots extend back to the 1980s, when both Daiichi and Sankyo established offices in Düsseldorf, Germany. Here, the merger between the two traditional Japanese enterprises took place in 2007. more...
Daiichi Sankyo intends to carry out its growth strategy in Europe and to increase net sales to €1.2 billion by 2012. The main growth driver to achieve this ambitious goal will be the company's business portfolio. more...
Daiichi Sankyo Europe has two production facilities, both approved by national and international authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMEA) and the German Institute for Drugs and Medical Devices (BfArM). more...